Related Experiment Video
Updated: Sep 25, 2026
Development of an Ethanol-induced Fibrotic Liver Model in Zebrafish to Study Progenitor Cell-mediated Hepatocyte Regeneration
Published on: May 13, 2016
Coexpression of Smad7 and UPA attenuates carbon tetrachloride-induced rat liver fibrosis
Baocan Wang1, Wenxi Li, Yingwei Chen
1Department of Gastroenterology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Background:
There is a great need for developing novel therapies to treat liver fibrosis. Previous studies showed that both Smad7 and uPA were inhibitors of liver fibrosis. Therefore, we explored the therapeutic effects of combinational gene therapy with Smad7 and uPA on CCl4-induced liver fibrosis.
Material/Methods:
Smad7 and uPA genes were cloned into an adenovirus vector. To observe the therapeutic effects of coexpression of Smad7 and uPA genes, the recombinant adenovirus were delivered into CCL4-induced fibrosis models. Fibrillar collagen, hydroxyproline, α-SMA, TGF-β1, MMP-13, TIMP-1, HGF and PCNA were detected to evaluate the fibrosis and to explore the mechanisms underlying the treatment with Smad7 and uPA.
Results:
The results showed that single Smad7 or uPA adenovirus reduced CCL4 induced liver fibrosis significantly; while combination of Smad7 and uPA had more significant therapeutic effect on CCl4 induced liver fibrosis. Then the markers underlying the therapeutic effect of combination of Smad7 and uPA were also explored. Over-expression of Smad7 and uPA inhibited the expression of α-SMA and TGF- β1 significantly. Combinational gene therapy also enhanced extracellular matrix degradation by increasing the expression of MMP-13, inhibiting TIMP-1 expression, and promoted hepatocyte proliferation, while single Smad7 or uPA only induced part of these changes.
Conclusions:
These results suggest that combinational gene therapy with Smad7 and uPA inhibited CCl4-induced rat liver fibrosis by simultaneously targeting multiple pathogenic pathways.
Insights
Combination gene therapy using Smad7 and urokinase plasminogen activator (uPA) shows significant therapeutic effects against liver fibrosis. This approach targets multiple disease pathways for enhanced treatment of liver fibrosis.
Area of Science:
- Hepatology
- Gene Therapy
- Fibrosis Research
Background:
- Liver fibrosis necessitates novel therapeutic strategies.
- Smad7 and uPA are known inhibitors of liver fibrosis.
- Investigating combined Smad7 and uPA gene therapy for liver fibrosis.
Purpose of the Study:
- To evaluate the therapeutic efficacy of combined Smad7 and uPA gene therapy.
- To explore the underlying mechanisms of this combined therapy in a CCl4-induced liver fibrosis model.
Main Methods:
- Cloning Smad7 and uPA genes into an adenovirus vector.
- Administering recombinant adenovirus to CCl4-induced liver fibrosis models.
- Assessing markers of fibrosis, extracellular matrix, and cell proliferation.
Main Results:
- Both single Smad7 or uPA and their combination significantly reduced liver fibrosis.
- Combined therapy demonstrated a more pronounced therapeutic effect than single agents.
- Co-expression of Smad7 and uPA inhibited α-SMA and TGF-β1, enhanced ECM degradation, and promoted hepatocyte proliferation.
Conclusions:
- Combined Smad7 and uPA gene therapy effectively inhibits CCl4-induced rat liver fibrosis.
- The therapy targets multiple pathogenic pathways simultaneously.
- This strategy offers a promising approach for treating liver fibrosis.
